Tasisulam(LY573636)|cas 519055-62-0|DC Chemicals|Price|Buy

Cas No.:	519055-62-0
Chemical Name:	Tasisulam
Synonyms:	Tasisulam;N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide;LY573636;N-(5-bromothiophen-2-yl)sulfonyl-2,4-dichlorobenzamide;N-(5-Bromothiophen-2-ylsulfonyl)-2,4-dichlorobenzamide;UNII-1YC4W9MSLJ;1YC4W9MSLJ;519055-62-0;DTXSID20199869;FT-0763021;AS-38576;HY-14804;AC-32975;P7M;Tasisulam(LY573636);Tasisulam [INN];J-522818;EX-A1367;Q27253184;SW219181-1;CCG-268827;HMS3653O12;BCP05154;s7326;NCGC00386305-05;LY 573636 (sodium);Benzamide, N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichloro-;BCP9000890;NS00069285;519055-63-1;SB19401;CHEMBL2110587;Z442229142;Tasisulam (sodium);AKOS027250790;N-((5-BROMOTHIOPHEN-2-YL)SULFONYL)-2,4-DICHLOROBENZAMIDE;N-[(5-bromothiophen-2-yl)sulfonyl]-2,4-dichlorobenzamide;TASISULAM [WHO-DD];SCHEMBL1581371;Tasisulam (LY573636);LY-573636;DB11941;CS-0003569;LY 573636;MFCD11973637;EN300-6492968;Tasisulam(LY573636)?;CHEBI:231621;tasisulamum;DB-071449;LY573636 sodium;DTXCID30122360;BRD-K42495768-001-01-7;n-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
SMILES:	O=C(NS(=O)(C1=CC=C(Br)S1)=O)C2=CC=C(Cl)C=C2Cl
Formula:	C₁₁H₆NO₃S₂Cl₂Br
M.Wt:	415.11024
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Tasisulam is a small molecule antitumor agent that inhibits mitotic progression and induces vascular normalization. Tasisulam induces apoptosis via the intrinsic pathway[1].

In Vitro:

Tasisulam (200 μM-200 nM; 48 hours) induces an antiproliferative response across a wide range of tumor histologies with EC50s is 10 μM and 25 μM for Calu-6 and A-375 cell lines, respectively[1]. Tasisulam (25, 50 μM; 72 hours) induces a concentration-dependent increase in 4N DNA and G2-M accumulation[1]. Tasisulam (200 μM-200 nM; 48 hours) induces apoptosis in a broad range of in vitro cancer cell models[1]. Cell Proliferation Assay[1] Cell Line: Calu-6 non-small cell lung carcinoma and A-375 melanoma models Concentration: 200 μM-200 nM Incubation Time: 48 hours Result: Induced an antiproliferative response across a wide range of tumor histologies with EC50s are 10 μM and 25 μM, respectively. Cell Cycle Analysis[1] Cell Line: Calu-6 and A-375 cell lines Concentration: 25, 50 μM Incubation Time: 72 hours Result: Induced a concentration-dependent increase in 4N DNA and G2-M accumulation. Apoptosis Analysis[1] Cell Line: Calu-6 non-small cell lung carcinoma and A-375 melanoma models Concentration: 200 μM-200 nM Incubation Time: 48 hours Result: Induced apoptosis in a broad range of in vitro cancer cell models.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC67413	MRT-23227
DC67412	MRT-3486
DC67411	MRT-7612
DC67410	MRT-10350
DC67407	IKZF1-degrader-1	IKZF1-degrader-1 (Compound 9-B) is a highly potent molecular glue that achieves sub-nanomolar degradation of IKZF1 (DC50 = 0.134 nM), demonstrating significant therapeutic potential for targeting IKZF1-dependent malignancies.
DC67406	EM12-FS	EM12-FS is a bifunctional CRBN modulator that engages cereblon at His353 while functioning as a molecular glue to induce NTAQ1 degradation. Demonstrating favorable pharmacokinetics, it exhibits a human plasma half-life of 196 minutes, supporting its therapeutic potential.
DC67405	Acetyl-cyclosporin A aldehyde	Acetyl-cyclosporin A aldehyde is a chemically modified derivative of cyclosporin A (HY-B0579), featuring an acetyl group and a reactive aldehyde moiety. The parent compound, cyclosporin A, is a dual-function molecule that both inhibits calmodulin signaling and binds cyclophilin, thereby blocking NF-AT nuclear translocation and inducing mitochondrial dysfunction.
DC67404	QS-57	QS-57 is a bifunctional degrader that combines BRD4-targeting PROTAC activity with 14-3-3 molecular glue properties.
DC67403	KRAS ligand 4	KRAS ligand 4 (compound 2) is a SOS1-targeting bifunctional molecular glue that suppresses oncogenic signaling by degrading key KRAS pathway components, evidenced by reduced pERK and pS6 levels. It demonstrates broad-spectrum activity against diverse KRAS mutations, disrupting proliferation across resistant cancer models.
DC67402	Pomalidomide-15N,13C5	Pomalidomide-15N,13C5 is a stable isotope-labeled variant of pomalidomide (HY-10984), a third-generation immunomodulatory drug that functions as a cereblon-directed molecular glue. This compound mediates targeted ubiquitination and degradation of Ikaros family transcription factors (IKZF1/3) through recruitment of the CRL4CRBN E3 ligase complex, underpinning its therapeutic mechanism.